Riskpilot← Back to searchSign inGet full accessGHN Pharma AB
ABActiveOrg 5565623716Flöjelbergsgatan 12Activities of business and employers membership organisations · NACE 9411Est. 19981-4 employees
Revenue 2024
SEK 1,9M
-4% vs 2023
EBITDA margin
-7.2%
-130% vs 2023
Equity ratio
99.5%
Financial strength
Net profit 2024
SEK 11,5M
+118% vs 2023
| Revenue | SEK 1,9M | -4% |
| EBITDA | SEK -138K | -130% |
| Net profit | SEK 11,5M | +118% |
| Total assets | SEK 105,5M | +10% |
| Equity | SEK 104,9M | +11% |
| Employees | — | — |
Legal name
GHN Pharma AB
Org number
5565623716
Legal form
Aktiebolag
NACE code
9411 · Activities of business and employers membership organisations
Founded
27 november 1998
Share capital
SEK 412 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva handel, service och konsultationer med utbildning och undersökningar avseende marknadsföring, försäljning och organisationsutveckling inom hälso- och sjukvårdssegmentet, förvalta fast och lös egendom, ävensom idka därmed förenlig verksamhet.
Address
Flöjelbergsgatan 12
Email
roland@ghnpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 1999 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 888 | — | — | 831 | 840 | 81 | 6 114 | 296 | 1 997 | 1 918 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 11 770 | 69 | 71 | −663 | −270 | −1 413 | −1 548 | −2 014 | −60 | −138 |
| Depreciation & amort. | −16 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 11 754 | 69 | 71 | −663 | −270 | −1 413 | −1 548 | −2 014 | −60 | −138 |
| Net financials | −23 | 1 347 | 60 808 | 2 238 | 10 693 | 1 646 | 16 920 | −3 393 | 5 339 | 11 785 |
| Profit before tax | 10 | 1 416 | 60 879 | 4 203 | 10 042 | 3 079 | 15 372 | −2 975 | 5 290 | 11 661 |
| Tax | −10 | −0 | −0 | −0 | −247 | −0 | −0 | −0 | −0 | −132 |
| Net profit | 11 721 | 1 416 | 60 879 | 4 203 | 9 795 | 3 079 | 15 372 | −2 975 | 5 290 | 11 529 |
| Item | 1999 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 871 | 6 401 | 65 719 | 67 168 | 77 504 | 79 870 | 94 545 | 90 619 | 95 545 | 105 479 |
| Equity | — | 5 176 | 63 765 | 66 868 | 76 453 | 79 351 | 94 203 | 90 409 | 94 698 | 104 928 |
| Long-term debt | 1 054 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 860 | 1 225 | 1 954 | 300 | 671 | 519 | 341 | 210 | 846 | 551 |
| Total debt | 2 914 | 1 225 | 1 954 | 300 | 671 | 519 | 341 | 210 | 846 | 551 |
EBITDA margin
-7.2%
This company
15.8%
Market median
-146% vs market
19992024
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
19992024
Return on equity
11.0%
This company
18.4%
Market median
+40% vs market
19992024
Net profit margin
601.1%
This company
8.1%
Market median
+7321% vs market
19992024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
19992024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
19992024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 1999Filed via Bolagsverket / SCB · Period 1998-11-01 – 1999-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UA | Audit | 2022 | — | — |
BR Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
KI Chief Auditor | Chief Auditor | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GHN Pharma AB 
GHN Pharma Metabolic ABBoard members of GHN Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Anders Göransson Borén | Audit | 0 companies |
| Bengt Roland Sandström | Chief Executive Officer | 0 companies |
| Kristofer Ingmar Håkansson | Chief Auditor | 0 companies |
| Tina Madsen Sandström | Deputy Board Member | 0 companies |